Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.35 |
| ▸ | WNT3A | P56704 | 3/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21824350 | 0.84 | HCRTR1 (0.39) | F2HCRTR1HCRTR2MRGPRX1HTR4 | |
| SCHEMBL21824388 | 0.80 | F2 (0.41) | F2HCRTR1HCRTR2MRGPRX1HTR4 | |
| Hydrochloric Acid SCHEMBL18039841 | 0.77 | F2 (0.69) | F2KLKB1KLK1 | |
| Hydrochloric Acid SCHEMBL21824318 | 0.75 | F2 (0.59) | F2KLKB1 | |
| SCHEMBL29905696 | 0.73 | HCRTR1 (0.43) | F2HCRTR1HCRTR2MRGPRX1HTR4 | |
| Hydrochloric Acid SCHEMBL21824341 | 0.71 | CHRNB2 (0.41) | F2KLKB1KLK1 | |
| SCHEMBL21824373 | 0.69 | F2 (0.41) | F2HCRTR1HCRTR2MRGPRX1HTR4 | |
| SCHEMBL21824339 | 0.68 | HRH4 (0.46) | F2 | |
| SCHEMBL29905499 | 0.68 | F2 (0.69) | F2KLKB1KLK1 | |
| SCHEMBL20474031 | 0.68 | CCNA2 (0.35) | F2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200109132-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109132-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINE1 | F2 30/4885HCRTR1 4622/4885HCRTR2 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.